Is universal screening for hepatitis C infection prior to commencing antitumour necrosis factor-α therapy necessary?

Abstract

Screening for hepatitis C virus (HCV) prior to the commencement of antitumour necrosis factor (anti-TNF)-α therapies for dermatological disease is recommended for all patients.

Keywords

• screening
• hepatitis
• necrosis